Search Results
Results found for "Keltic Pharma Therapeutics"
Posts (331)
- AELIS PHARMA launches their IPO for €25 million
February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews
- ShouTi Pharma has a brand new website
January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing medicines for people around the world." Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc.
Other Pages (100)
- how-to-build-breakthrough-gpcr-programs | Dr. GPCR Ecosystem
Andrew Tobin draws from his experience leading translational GPCR programs and co-founding Keltic Pharma As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel
- Dr. Graeme Milligan | Dr. GPCR Ecosystem
Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology company co-founded by Andrew with series A funding from the European
Events (2)
- Development of GPCR Ligands as Therapeutic DrugsTickets: $0.00March 20, 2025Â |Â 2:00 PM
- Practical Quantification of Allosteric ModulationTickets: $0.00May 1, 2025Â |Â 2:00 PM
